TAK
Takeda PharmaceuticalCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Bull case: Successful clinical readouts, clearer post-quarter guidance, and tangible cost-synergy realization drive re-rating toward the analyst high (19.5). Stronger-than-expected launch execution or an accretive licensing/M&A outcome would add incremental upside.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
Failure to deliver integration synergies or cost savings
Momentum
29
Value
64
Sentiment
48
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $19.50 · Bear $14.87
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-30 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.69
Why
Momentum29 · Δ7d +25.3
Value64 · Δ7d -0.2
Sentiment48 · Δ7d -5.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
29
26% active weight
Current posture
7d trendImproving
Δ7d
+25.3
Δ21d
+15.1
Value
64
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.6
Sentiment
48
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.7
Δ21d
-9.0
Why this grade
Composite grade C. Momentum 29.1 / Value 64.2 / Sentiment 47.9
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$53.2B
Beta
0.05
Shares Out
3.18B
P/E (TTM)
226.9
P/S (TTM)
1.77
P/FCF (TTM)
12.72
Rev YoY
+0.9%
EPS YoY
+246.7%
Gross Margin
+53.5%
Op Margin
+5.6%
Net Debt
$30.68B
Current Ratio
1.09
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology